QALYs and Ethics Prof. dr. Jan van Busschbach 11.

Slides:



Advertisements
Similar presentations
Health Economics for Prescribers
Advertisements

ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.
Quality of life in relation to costs
QALY: veel bekritiseerd, maar nooit meer dan het alternatief”
Quality of life (Utility) Measurements In Relation to Health Economics
Disability Adjusted Life Years Possibilities and Problems Trude M. Arnesen, Ole Frithjof Norheim.
Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
Justice and Economic Evaluation Prof. Dr. Jan Busschbach
We show that MP can be used to allocate resources to treatments within and between patient populations, using a policy-relevant example. The outcome is.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Utility Assessment HINF Medical Methodologies Session 4.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
Departing from the health maximisation approach Social value judgements made by NICE’s advisory committees Koonal K. Shah Office of Health Economics, UK.
Quality of life Assessment introduction
Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
QALYs and Ethics Is there an ethical / valid alternative?
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Overview of the EQ-5D Purpose and origins of the descriptive system.
BIOE 301 Lecture Thirteen. HIV/AIDS Vaccine Update.
Summary of measures of population Health Farid Najafi MD PhD School of Population Health Kermanshah University of Medical Sciences.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
Lecture Thirteen Biomedical Engineering for Global Health.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
Disability Adjusted Life Years
1 QALY, Burden of Disease and Budget Impact  Jan J.V. Busschbach, Ph.D.  Erasmus MC, Rotterdam, The Netherlands  
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
PHARMAC What is PHARMAC? PHARMAC - the Pharmaceutical Management AgencyPHARMAC - the Pharmaceutical Management Agency A New Zealand Government Agency (Crown.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Cost Effectiveness  Jan J.V. Busschbach, Ph.D.  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
WPA Educational Programme on Depressive Disorders Volume One: Fundamentals Copyright © World Psychiatric Association.
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Health Economic Course Series
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
BIOE 301 Lecture Sixteen. Review of Lectures What is the goal of cancer screening? Successful cancer screening examples? Can screening hurt more.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Why does SMC say NO We all want the most effective medicines All medicines cost money Health budgets are limited How do we choose?
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
Cost effectiveness Analysis: Valuing Health; Valuing Research!
Global burden of diseases
Italy - Evidence package
Prof. Md Sayedur Rahman Pharmacoeconomics: Bangladesh Perspective
Musculoskeletal Health in Europe
Biomedical Engineering for Global Health
Justification treatment cost
Example choice set: DAS28, 28 joint disease activity score; EUR, Euro; QALY, quality-adjusted life year. * In the choice sets, changes of the individual.
Volume 375, Issue 9723, Pages (April 2010)
Different measures of health status of Australians
Presentation transcript:

QALYs and Ethics Prof. dr. Jan van Busschbach 11

Health Economics  Comparing different allocations  Should we spend our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome  Outcomes must be comparable  Make a generic outcome measure 2

Outcomes in health economics  Specific outcomes are incompatible  Allow only for comparisons within the specific field Clinical successes: successful operation, total cure Clinical failures: “events” “Hart failure” versus “second psychosis”  Generic outcome are compatible  Allow for comparisons between fields Life years Quality of life  Most generic outcome  Quality adjusted life year (QALY) 3

 Example  Blindness  Time trade-off value is 0.5  Life span = 80 years  0.5 x 80 = 40 QALYs Quality Adjusted Life Years (QALY) X Life years x 80 = 40 QALYs

Area under the curve

Cost per QALY 6  20 QALY gained  €  Cost per QALY  € /20 QALYs = €5.000/QALY

QALY league table 7

Ethical critics on QALY 8

In the past, much criticism Cohen CB. Quality of life and the analogy with the Nazis. Journal of Medicine and Philosophy 8: , 1983.

Criticism remains 10 ….the strictly fascist essence of those QALYs (so-called Quality- Adjusted Life Years)…

QALY publications

12 Three problems with the ethical criticism ….. 1. Arguments represent aversion toward a limited budget 2. Proposed alternatives turn out to be the same 3. Even equity concerns are in need of QALY

1. Arguments often represent aversion limited budget 13 “…Wij hebben duidelijk aangegeven dat een discussie over "wat maatschappelijk nog aanvaardbaar is" [kosten per QALY] alleen gevoerd mag worden als geldverslindende "frivoliteiten" door de maatschappij […] zijn uitgebannen. Bijvoorbeeld "joint strike fighters“… Kees van Bezooijen in his roll as Patient representative, 2007

2. Proposed alternative turns out to be the same… 14  TWiST  Time Without Symptoms of disease and subjective Toxic effects of treatment  HYE  Health Years Equivalent  SAVE  Saved Young Life Equivalent  Capabilities  Amartya Sen  DALY  Disability Adjusted Life Years

15 Burden of Disease Project  WHO Global Burden of Disease (GBD)  Impact of diseases world wide  Estimates of epidemiology per disease  Mortality  Quality of life losses  In need of one measure of health  But WHO disliked QALY…

16 Chris Murray  Harvard  School of Public Health  Worked outside  Health economics  Med Decision Making  DALY  Disability Adjusted Life Years  Lost life years  Lost Quality of life

17 DALY / QALY DALY QALY

ABC Kwaliteit van leven 3. Equity 18 Efficiency Equity

Is (should) burden (be) a criterion? 19 Pronk & Bonsel, Eur J Health Econom 2004, 5:

ABC Levensjaen Costs/QALY as indicator of solidarity € € €

Costs/QALY versus Burden of disease 21 € € € € € 0 Burden of disease X X X X X Equity / Burden / DALY

22 Dutch Council for Public Health and Health Care (De Raad voor de Volksgezondheid en Zorg, 2006)

23 Three problems with the ethical criticism ….. 1. Arguments represent aversion toward a limited budget 2. Proposed alternatives turn out to be the same 3. Even equity concerns are in need of QALY